Literature DB >> 24077280

Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression.

F Bengsch1, A Buck2, S C Günther2, J R Seiz2, M Tacke2, D Pfeifer3, D von Elverfeldt4, L Sevenich5, L E Hillebrand6, U Kern1, M Sameni7, C Peters8, B F Sloane9, T Reinheckel8.   

Abstract

The cysteine protease cathepsin B (CTSB) is frequently overexpressed in human breast cancer and correlated with a poor prognosis. Genetic deficiency or pharmacological inhibition of CTSB attenuates tumor growth, invasion and metastasis in mouse models of human cancers. CTSB is expressed in both cancer cells and cells of the tumor stroma, in particular in tumor-associated macrophages (TAM). In order to evaluate the impact of tumor- or stromal cell-derived CTSB on Polyoma Middle T (PyMT)-induced breast cancer progression, we used in vivo and in vitro approaches to induce human CTSB overexpression in PyMT cancer cells or stromal cells alone or in combination. Orthotopic transplantation experiments revealed that CTSB overexpression in cancer cells rather than in the stroma affects PyMT tumor progression. In 3D cultures, primary PyMT tumor cells showed higher extracellular matrix proteolysis and enhanced collective cell invasion when CTSB was overexpressed and proteolytically active. Coculture of PyMT cells with bone marrow-derived macrophages induced a TAM-like macrophage phenotype in vitro, and the presence of such M2-polarized macrophages in 3D cultures enhanced sprouting of tumor spheroids. We employed a doxycycline (DOX)-inducible CTSB expression system to selectively overexpress human CTSB either in cancer cells or in macrophages in 3D cocultures. Tumor spheroid invasiveness was only enhanced when CTSB was overexpressed in cancer cells, whereas CTSB expression in macrophages alone did not further promote invasiveness of tumor spheroids. We conclude that CTSB overexpression in the PyMT mouse model promotes tumor progression not by a stromal effect, but by a direct, cancer cell-inherent mode of action: CTSB overexpression renders the PyMT cancers more invasive by increasing proteolytic extracellular matrix protein degradation fostering collective cell invasion into adjacent tissue.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24077280      PMCID: PMC4139469          DOI: 10.1038/onc.2013.395

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

1.  Controlling the false discovery rate in behavior genetics research.

Authors:  Y Benjamini; D Drai; G Elmer; N Kafkafi; I Golani
Journal:  Behav Brain Res       Date:  2001-11-01       Impact factor: 3.332

Review 2.  Cancer and the chemokine network.

Authors:  Fran Balkwill
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

3.  A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen.

Authors:  R A Maciewicz; D J Etherington
Journal:  Biochem J       Date:  1988-12-01       Impact factor: 3.857

4.  Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues.

Authors:  M R Buck; D G Karustis; N A Day; K V Honn; B F Sloane
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

5.  Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1).

Authors:  Megan K Houseweart; Len A Pennacchio; Alex Vilaythong; Christoph Peters; Jeffrey L Noebels; Richard M Myers
Journal:  J Neurobiol       Date:  2003-09-15

6.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.

Authors:  Johanna A Joyce; Amos Baruch; Kareem Chehade; Nicole Meyer-Morse; Enrico Giraudo; Fong-Ying Tsai; Doron C Greenbaum; Jeffrey H Hager; Matthew Bogyo; Douglas Hanahan
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

7.  Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis.

Authors:  Sajani S Lakka; Christopher S Gondi; Niranjan Yanamandra; William C Olivero; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  Oncogene       Date:  2004-06-10       Impact factor: 9.867

8.  Cathepsins B, H and L in human breast carcinoma.

Authors:  D Gabrijelcic; B Svetic; D Spaić; J Skrk; M Budihna; I Dolenc; T Popovic; V Cotic; V Turk
Journal:  Eur J Clin Chem Clin Biochem       Date:  1992-02

9.  Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization.

Authors:  A A Sinha; D F Gleason; O F Deleon; M J Wilson; B F Sloane
Journal:  Anat Rec       Date:  1993-02

10.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.

Authors:  C T Guy; R D Cardiff; W J Muller
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

View more
  42 in total

1.  Analyzing the Role of Proteases in Breast Cancer Progression and Metastasis Using Primary Cells from Transgenic Oncomice.

Authors:  Olga Vasiljeva; Lisa Sevenich; Thomas Reinheckel
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Pathomimetic cancer avatars for live-cell imaging of protease activity.

Authors:  Kyungmin Ji; Joshua Heyza; Dora Cavallo-Medved; Bonnie F Sloane
Journal:  Biochimie       Date:  2015-09-12       Impact factor: 4.079

Review 3.  Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes.

Authors:  Reik Löser; Jens Pietzsch
Journal:  Front Chem       Date:  2015-06-23       Impact factor: 5.221

4.  Interactions of human MSC with head and neck squamous cell carcinoma cell line PCI-13 reduce markers of epithelia-mesenchymal transition.

Authors:  F Böhrnsen; M Fricke; C Sander; A Leha; H Schliephake; F J Kramer
Journal:  Clin Oral Investig       Date:  2014-10-28       Impact factor: 3.573

5.  Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.

Authors:  Mansoureh Sameni; Elizabeth A Tovar; Curt J Essenburg; Anita Chalasani; Erik S Linklater; Andrew Borgman; David M Cherba; Arulselvi Anbalagan; Mary E Winn; Carrie R Graveel; Bonnie F Sloane
Journal:  Clin Cancer Res       Date:  2015-10-02       Impact factor: 12.531

6.  Combinatorial Omics Analysis Reveals Perturbed Lysosomal Homeostasis in Collagen VII-deficient Keratinocytes.

Authors:  Kerstin Thriene; Björn Andreas Grüning; Olivier Bornert; Anika Erxleben; Juna Leppert; Ioannis Athanasiou; Ekkehard Weber; Dimitra Kiritsi; Alexander Nyström; Thomas Reinheckel; Rolf Backofen; Cristina Has; Leena Bruckner-Tuderman; Jörn Dengjel
Journal:  Mol Cell Proteomics       Date:  2018-01-11       Impact factor: 5.911

Review 7.  Cathepsin B: multiple roles in cancer.

Authors:  Neha Aggarwal; Bonnie F Sloane
Journal:  Proteomics Clin Appl       Date:  2014-03-26       Impact factor: 3.494

Review 8.  Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

Authors:  Achilleas D Theocharis; Chrisostomi Gialeli; Panagiotis Bouris; Efstathia Giannopoulou; Spyros S Skandalis; Alexios J Aletras; Renato V Iozzo; Nikos K Karamanos
Journal:  FEBS J       Date:  2014-11-06       Impact factor: 5.542

9.  Prognostic and therapeutic relevance of cathepsin B in pediatric acute myeloid leukemia.

Authors:  Garima Pandey; Sameer Bakhshi; Manoj Kumar; Bhaskar Thakur; Prerna Jain; Punit Kaur; Shyam S Chauhan
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

10.  Split top: a maternal cathepsin B that regulates dorsoventral patterning and morphogenesis.

Authors:  Yvette G Langdon; Ricardo Fuentes; Hong Zhang; Elliott W Abrams; Florence L Marlow; Mary C Mullins
Journal:  Development       Date:  2016-02-18       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.